Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,728,532 papers from all fields of science
Search
Sign In
Create Free Account
4-hydroxyifosfamide
Known as:
4-hydroxy-ifosfamide
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Ifosfamide
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Influence of Short-Term Use of Dexamethasone on the Pharmacokinetics of Ifosfamide in Patients
S. K. Brüggemann
,
Sonja Pfäffle
,
S. Peters
,
T. Wagner
Drug Metabolism And Disposition
2007
Corpus ID: 13996914
Dexamethasone induces the hepatic cytochrome P450 3A and, therefore, is predicted to change the pharmacokinetics, activities, and…
Expand
2004
2004
Hypersensitivity pneumonitis associated with the use of trofosfamide.
H. Kopp
,
Lothar Kanz
,
J. Hartmann
Anti-Cancer Drugs
2004
Corpus ID: 39206524
Trofosfamide (Ixoten; Baxter Oncology, Germany) is an alkylating agent that, as with other oxazaphosphorine derivatives, has to…
Expand
2001
2001
Modulation of the cytochrome P450–mediated metabolism of ifosfamide by ketoconazole and rifampin
T. Kerbusch
,
R. Jansen
,
+4 authors
J. Beijnen
Clinical pharmacology and therapy
2001
Corpus ID: 10905675
The autoinducible metabolic transformation of the anticancer agent ifosfamide involves activation through 4‐hydroxyifosfamide to…
Expand
2001
2001
Distribution of ifosfamide and metabolites between plasma and erythrocytes.
T. Kerbusch
,
V. Herben
,
M. Jeuken
,
J. Ouwerkerk
,
H. Keizer
,
J. Beijnen
Biopharmaceutics & drug disposition
2001
Corpus ID: 8074031
The distribution of ifosfamide (IF) and its metabolites 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE), 4…
Expand
1997
1997
Quantification of 4-hydroxyifosfamide in plasma of ifosfamide-treated mice
R. Struck
,
D. M. McCain
,
S. W. Tendian
,
K. Tillery
Cancer Chemotherapy and Pharmacology
1997
Corpus ID: 13554816
Purpose: Ifosfamide is becoming an important clinical anticancer drug. Meaningful pharmacology studies require quantification of…
Expand
1995
1995
Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: synthesis and deuterium labeling for applications to metabolite quantification.
S. Ludeman
,
E. M. Shulman-Roskes
,
+4 authors
O. Colvin
Journal of Pharmacy and Science
1995
Corpus ID: 21575019
There is ongoing interest in the selective, quantitative analysis of the cyclophosphamide metabolites 4-hydroxycyclophosphamide…
Expand
1994
1994
Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
J. Boal
,
S. Ludeman
,
C. K. Ho
,
J. Engel
,
U. Niemeyer
Arzneimittel-Forschung
1994
Corpus ID: 20965804
31P nuclear magnetic resonance (NMR) spectroscopy was used in conjunction with cell perfusion techniques to monitor the…
Expand
1989
1989
Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues.
C. Kwon
,
R. Borch
Journal of Medicinal Chemistry
1989
Corpus ID: 45941437
The activation mechanisms of the N-substituted 4-hydroxycyclophosphamide analogues 4-hydroxyifosfamide (2b), 4…
Expand
1985
1985
Fluorometric determination of 4-hydroxyifosfamide in blood and urine.
I. Ikeuchi
,
T. Amano
Chemical and pharmaceutical bulletin
1985
Corpus ID: 13110539
A sensitive fluorometric method using 3-aminophenol was developed to measure 4-hydroxyifosfamide, the active metabolite of the…
Expand
1983
1983
Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
J. Low
,
R. Borch
,
N. Sládek
Cancer Research
1983
Corpus ID: 28033969
The rates at which the 4-hydroxyoxazaphosphorines, 4-hydroxycyclophosphamide and 4-hydroxyifosfamide, are converted to reactive…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE